The Congestive Heart Failure market report also offers comprehensive insights into the Congestive Heart Failure market size, share, Congestive Heart Failure epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Congestive Heart Failure market size growth forward.
Some of the key highlights from the Congestive Heart Failure Market Insights Report:
-
Several key pharmaceutical companies, including Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, and others, are developing novel products to improve the Congestive Heart Failure treatment outlook.
-
In March 2024, the FDA granted a label expansion for Novo Nordisk’s Wegovy (semaglutide) to help reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight. This approval was supported by data from the Phase III SELECT trial, which demonstrated that a 2.4 mg injection of Wegovy resulted in a 20% reduction in major adverse cardiovascular events compared to a placebo, when used alongside standard care.
-
In December 2024, Gerresheimer revealed that the FDA had given tentative approval to SQ Innovation for Lasix ONYU, a treatment for fluid overload in congestive heart failure to be administered at home.
-
In 2023, the total market size for Congestive Heart Failure (Congestive Heart Failure) in the 7MM was approximately USD 6,900 million, with the growing prevalence of the disease expected to drive market expansion during the forecast period from 2024 to 2034. According to the 2023 Heart Disease and Stroke Statistics report, the prevalence of heart failure is increasing due to factors such as an aging population, improved treatment and survival rates for ischemic heart disease, and the availability of effective therapies that extend the lives of heart failure patients.
-
The United States accounted for the highest number of prevalent heart failure cases among the 7MM in 2023.
-
Off-label therapies and generics dominate the current Congestive Heart Failure market due to their affordability and easy accessibility for patients. Generic versions of medications such as olmesartan, eplerenone, furosemide, and candesartan cilexetil are widely available, creating significant competition for newly developed drugs and hindering market growth.
-
Key players like AstraZeneca (FORXIGA), Novartis (ENTRESTO), Eli Lilly, and Boehringer Ingelheim (JARDIANCE) are increasingly focusing on label expansions and gaining approvals for treatments that can be used across a broader patient population, which is expected to drive the Congestive Heart Failure drug market forward.
-
The FDA approval of FUROSCIX represents a significant breakthrough in heart failure treatment, enabling certain patients to avoid costly hospitalizations by self-administering treatment at home, thus offering considerable cost savings without compromising patient well-being. This innovation is likely to be highly attractive to healthcare providers.
-
As per DelveInsight analysis, the Congestive Heart Failure market is anticipated to witness growth at a considerable CAGR.
Strategise your business goals by understanding market dynamics @ Congestive Heart Failure Market Landscape
Congestive Heart Failure Overview
Congestive Heart Failure (Congestive Heart Failure), also known as heart failure, is a chronic, progressive condition where the heart is unable to produce a cardiac output that meets the body’s demands without increasing diastolic pressure, often due to cardiac diseases that affect either the systolic or diastolic function of the ventricles. Heart failure is typically classified based on left ventricular ejection fraction (LVEF). Heart failure with a normal LVEF (≥50%) is referred to as heart failure with preserved ejection fraction, while heart failure with reduced LVEF (<40%) is termed heart failure with reduced ejection fraction. Heart failure with an LVEF between 40-49% is categorized as heart failure with mid-range ejection fraction (HFmrEF). In the early stages, Congestive Heart Failure symptoms are subtle and often mistaken for typical signs of aging. The symptoms arise mainly due to fluid buildup or congestion, which causes blockage in the blood vessels. This congestion often starts in the lungs and then spreads to other parts of the body.
Congestive Heart Failure (Congestive Heart Failure) is a chronic condition where the heart cannot produce enough output to meet the body’s demands without causing increased diastolic pressure. This condition results from cardiac diseases affecting either the systolic or diastolic function of the heart. Congestive Heart Failure is commonly categorized based on left ventricular ejection fraction (LVEF). When the LVEF is ≥50%, it is called heart failure with preserved ejection fraction (HFpEF), while an LVEF <40% is termed heart failure with reduced ejection fraction (HFrEF). An LVEF between 40-49% is classified as heart failure with mid-range ejection fraction (HFmrEF). Early signs of Congestive Heart Failure are often mistaken for typical aging symptoms. Common symptoms are caused by fluid buildup, leading to blockages in blood vessels, with congestion beginning in the lungs and spreading to other parts of the body.
Do you know the treatment paradigms for different countries? Download our Congestive Heart Failure Market Sample Report
Congestive Heart Failure Epidemiology Insights
-
The analysis of Congestive Heart Failure in the 7MM draws a clear scenario which showed that the patients with HFpEF have a larger proportion (i.e., ~50%) because the heart is not severely affected but keeps on working through medication or symptomatic treatment, whereas, in the case of HFrEF, the patient’s heart is majorly affected. With growing age, the pumping rate of the heart declines.
-
In 2023, among all the four New York Heart Association (NYHA) Classes of heart failure, Class II accounted for around 45% of the total diagnosed heart failure cases in the 7MM.
Congestive Heart Failure Epidemiology Segmentation
DelveInsight’s Congestive Heart Failure market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Congestive Heart Failure historical patient pools and forecasted Congestive Heart Failure patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Congestive Heart Failure Market report proffers epidemiological analysis for the study period 2020-32 in the 7MM segmented into:
-
Congestive Heart Failure Prevalence
-
Age-Specific Congestive Heart Failure Prevalence
-
Gender-Specific Congestive Heart Failure Prevalence
-
Diagnosed and Treatable Cases of Congestive Heart Failure
Visit for more @ Congestive Heart Failure Epidemiological Insights
Congestive Heart Failure Market Insights:
-
The Congestive Heart Failure market in the 7MM was valued at around USD 6,900 million in 2023, with projections indicating growth during the forecast period from 2024 to 2034. The United States held the largest share of the total Congestive Heart Failure market and is expected to see significant market growth throughout the forecast period.
-
Among the EU4 and the UK, Germany had the highest market revenue share in 2023, while the United Kingdom had the smallest share.
Congestive Heart Failure Market Outlook
After a decade of limited new treatments, the FDA approved new classes of medications for congestive heart failure (Congestive Heart Failure) patients. These include ENTRESTO (sacubitril/valsartan), a combined angiotensin receptor-neprilysin inhibitor (ARNI), and CORLANOR (ivabradine), a sinoatrial node modulator. Both are part of a comprehensive medical therapy regimen. Additionally, VERQUVO (vericiguat), approved in January 2021, is a recent addition aimed at reducing the risk of cardiovascular death, heart failure hospitalizations, or the need for outpatient intravenous diuretics. It’s intended for adults with symptomatic chronic heart failure and an ejection fraction under 45%.
SGLT2 inhibitors, such as dapagliflozin and empagliflozin, have been shown to reduce heart failure hospitalization and cardiovascular death in HFrEF patients already on guideline-directed medical therapy, regardless of type 2 diabetes. The current Congestive Heart Failure treatment landscape offers various drugs with different mechanisms of action, providing safe and tolerable options for patients.
Many companies are investing in diverse treatment approaches for Congestive Heart Failure, including SGLT2 inhibitors, cardiac myosin activators, myeloperoxidase inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and cell therapies. These innovations are expected to drive future market growth. Notable upcoming drugs, such as finerenone, tirzepatide, semaglutide, and omecamtiv mecarbil, offer promising new mechanisms for treating Congestive Heart Failure.
Key players, including Bayer (finerenone), Eli Lilly (tirzepatide), Novo Nordisk (semaglutide), BioCardia (CardiAMP Cell Therapy), and others, are progressing through various stages of clinical development with their lead candidates, and others
Congestive Heart Failure Marketed Drugs
-
ENTRESTO: Novartis
-
JARDIANCE: Boehringer Ingelheim and Eli Lilly
Congestive Heart Failure Emerging Drugs
-
KERENDIA (finerenone): Bayer
-
MOUNJARO (tirzepatide): Eli Lilly and Company
Congestive Heart Failure Key Companies
-
Novartis, Boehringer Ingelheim, Eli Lilly, Bayer, Merck, AstraZeneca, Amgen, Otsuka Pharmaceutical, Cytokinetics, Mesoblast, Novo Nordisk, Lexicon Pharmaceuticals, scPharmaceuticals, Bristol-Myers Squibb, Intra-Cellular Therapies, Tenax Therapeutics, BioCardia, and others.
For more information, visit Congestive Heart Failure Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Congestive Heart Failure Market Report:
-
11 Years Forecast
-
7MM Coverage
-
Descriptive overview of Congestive Heart Failure, causes, signs and symptoms, diagnosis, treatment
-
Comprehensive insight into Congestive Heart Failure epidemiology in the 7MM
-
Congestive Heart Failure marketed and emerging therapies
-
Congestive Heart Failure companies
-
Congestive Heart Failure market drivers and barriers
Table of Contents:
1 Congestive Heart Failure Market Key Comprehensive Insights
2 Congestive Heart Failure Market Report Introduction
3 Competitive Intelligence Analysis for Congestive Heart Failure
4 Congestive Heart Failure Market Analysis Overview at a Glance
5 Executive Summary of Congestive Heart Failure
6 Congestive Heart Failure Epidemiology and Market Methodology
7 Congestive Heart Failure Epidemiology and Patient Population
8 Congestive Heart Failure Patient Journey
9 Congestive Heart Failure Treatment Algorithm, Congestive Heart Failure Current Treatment, and Medical Practices
10 Key Endpoints in Congestive Heart Failure Clinical Trials
11 Congestive Heart Failure Marketed Therapies
12 Congestive Heart Failure Emerging Therapies
13 Congestive Heart Failure: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Congestive Heart Failure
16 Congestive Heart Failure Market Key Opinion Leaders Reviews
18 Congestive Heart Failure Market Drivers
19 Congestive Heart Failure Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Congestive Heart Failure Epidemiology 2034
DelveInsight’s “Congestive Heart Failure – Epidemiology Forecast to 2034” report delivers an in-depth understanding of the disease, historical and forecasted Congestive Heart Failure epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Congestive Heart Failure Pipeline 2024
“Congestive Heart Failure Pipeline Insights, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Congestive Heart Failure market. A detailed picture of the Congestive Heart Failure pipeline landscape is provided, which includes the disease overview and Congestive Heart Failure treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/